Vaš brskalnik ne omogoča JavaScript!
JavaScript je nujen za pravilno delovanje teh spletnih strani. Omogočite JavaScript ali pa uporabite sodobnejši brskalnik.
Nacionalni portal odprte znanosti
Odprta znanost
DiKUL
slv
|
eng
Iskanje
Brskanje
Novo v RUL
Kaj je RUL
V številkah
Pomoč
Prijava
Early cost-effectiveness analysis of electrochemotherapy as a prospect treatment modality for skin melanoma
ID
Pirc, Eva
(
Avtor
),
ID
Federici, Carlo
(
Avtor
),
ID
Bošnjak, Maša
(
Avtor
),
ID
Perić, Barbara
(
Avtor
),
ID
Reberšek, Matej
(
Avtor
),
ID
Pecchia, Leandro
(
Avtor
),
ID
Glumac, Nebojša
(
Avtor
),
ID
Čemažar, Maja
(
Avtor
),
ID
Snoj, Marko
(
Avtor
),
ID
Serša, Gregor
(
Avtor
),
ID
Miklavčič, Damijan
(
Avtor
)
PDF - Predstavitvena datoteka,
prenos
(1,22 MB)
MD5: 302A0F5ADDB199AB5781BD0F0FF4B566
URL - Izvorni URL, za dostop obiščite
https://www.sciencedirect.com/science/article/pii/S0149291820303234
Galerija slik
Izvleček
Purpose: Electrochemotherapy is increasingly entering into national and international guidelines, requiring formal evaluation of treatment costs and cost-effectiveness to ensure that its uptake provides value to budget-constrained health care systems. This study analyzed the early cost-effectiveness of electrochemotherapy in patients with Stage IIIc/IV skin melanoma in clinical practice in Slovenia. The costs of electrochemotherapy were compared to those of the standard of care, consisting of palliative treatment and therapy for symptoms. Methods: The study enrolled 23 patients treated with electrochemotherapy at the Institute of Oncology (Ljubljana, Slovenia). The mean cost of electrochemotherapy was estimated using patient-specific cost data on electrochemotherapy procedures and subsequent follow-up. Quality-adjusted life-years (QALYs) were estimated by collecting EQ-5D-3L questionnaires at baseline, after complete or partial response following the treatment, and after a relapse of skin lesions. A discrete-time Markov model was built to estimate the lifetime costs and consequences of using electrochemotherapy compared to standard of care, from the perspective of the Slovenian health care system. The analysis was conducted separately in the whole patient sample and in the subset of patients with bleeding lesions. Deterministic and probabilistic sensitivity analyses were conducted to test model assumptions and to characterize the uncertainty around model parameters. Findings: In the whole patient population, electrochemotherapy for skin melanoma Stage IIIc/IV was expected to increase QALYs by 0.29 (95% credible interval [CrI], 0.10–0.50), at the higher cost of 6568 EUR (95% CrI, 4593–8928) in comparison to the standard of care. At the cost-effectiveness threshold of 20,000 EUR/QALY, the estimated probabilities of electrochemotherapy being cost-effective compared to standard of care were 0.30 and 0.91 in the whole patient sample and in patients with bleeding lesions, respectively. In the whole sample population, a 50% reduction in the price of the electrodes was expected to increase the probability of electrochemotherapy being cost-effective from 0.30 to ~0.64. Implications: The findings from this cost-effectiveness analysis of data from clinical practice were based on a small sample size (ie, 23 patents), which made the subgroup of patients with bleeding lesions very small. Therefore, the findings in this patient population should be carefully interpreted.
Jezik:
Angleški jezik
Ključne besede:
skin cancer
,
melanoma
,
electrochemotherapy
,
electroporation
,
cost-effectiveness
Vrsta gradiva:
Članek v reviji
Tipologija:
1.01 - Izvirni znanstveni članek
Organizacija:
FE - Fakulteta za elektrotehniko
Status publikacije:
Objavljeno
Različica publikacije:
Objavljena publikacija
Leto izida:
2020
Št. strani:
Str. 1535-1548.e2
Številčenje:
Vol. 42, no. 8
PID:
20.500.12556/RUL-138389
UDK:
616.5
ISSN pri članku:
0149-2918
DOI:
10.1016/j.clinthera.2020.06.013
COBISS.SI-ID:
24509699
Datum objave v RUL:
19.07.2022
Število ogledov:
760
Število prenosov:
100
Metapodatki:
Citiraj gradivo
Navadno besedilo
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Kopiraj citat
Objavi na:
Gradivo je del revije
Naslov:
Clinical therapeutics
Skrajšan naslov:
Clin. ther.
Založnik:
Elsevier
ISSN:
0149-2918
COBISS.SI-ID:
17552645
Licence
Licenca:
CC BY-NC-ND 4.0, Creative Commons Priznanje avtorstva-Nekomercialno-Brez predelav 4.0 Mednarodna
Povezava:
http://creativecommons.org/licenses/by-nc-nd/4.0/deed.sl
Opis:
Najbolj omejujoča licenca Creative Commons. Uporabniki lahko prenesejo in delijo delo v nekomercialne namene in ga ne smejo uporabiti za nobene druge namene.
Sekundarni jezik
Jezik:
Slovenski jezik
Ključne besede:
rak kože
,
melanom
,
elektrokemoterapija
,
elektroporacija
,
stroškovna učinkovitost
Projekti
Financer:
Drugi - Drug financer ali več financerjev
Program financ.:
COST
Številka projekta:
BM1309
Naslov:
European network for innovative uses of EMFs in biomedical applications
Financer:
ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:
P2-0249
Naslov:
Elektroporacija v biologiji, biotehnologiji in medicini
Financer:
ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:
P3-0003
Naslov:
Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev
Financer:
ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:
J2-9227
Naslov:
Elektroporacijske terapije z novimi visokofrekvenčnimi elektroporacijskimi pulzi
Financer:
ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Program financ.:
Young researchers
Podobna dela
Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:
Nazaj